Likely, we suspected that the mutated KIT and/or mutated WT1 could play a crucial role in the progression of low M-RiskScore AML patients, while mutations of NPM1 and/or RUNX1 endows worse progression in high M-RiskScore patients. Here, WT1 is linked to acute myeloid leukemia.